What are the key biomarkers in breast cancer

Key Biomarkers in Breast Cancer

Biomarkers are measurable characteristics of your cancer that help doctors understand how it will behave and which treatments are most likely to work. Think of them as the cancer's "fingerprint" — they tell your care team important information about your specific tumor.

The Three Essential Biomarkers

According to the NCCN Guidelines for Patients: Breast Cancer, your pathology report will include testing for three critical biomarkers:

1. Estrogen Receptor (ER) Status

• What it means: This test checks whether your cancer cells have receptors (like locks) that respond to the hormone estrogen
• ER-positive (ER+): Your cancer feeds on estrogen, which typically opens up hormone therapy options
• ER-negative (ER-): Your cancer doesn't respond to estrogen, so hormone therapies won't be effective
• Clinical significance: ER status is one of the most important factors in treatment planning

2. Progesterone Receptor (PR) Status

• What it means: Similar to ER testing, this checks if your cancer responds to the hormone progesterone
• PR-positive (PR+): Your cancer may respond to hormone-blocking treatments
• PR-negative (PR-): Hormone therapies targeting progesterone won't be effective
• How it's used: Often considered alongside ER status when planning hormone therapy

3. HER2 Status

• What it means: HER2 is a protein that can appear on cancer cells. This test measures whether your cancer has too much of this protein
• HER2-positive (HER2+): Your cancer has high levels of HER2, which typically means targeted therapies (like trastuzumab/Herceptin) can be very effective
• HER2-negative (HER2-): Your cancer doesn't have high HER2 levels, so HER2-targeted drugs won't be used
• Clinical significance: HER2 status significantly influences treatment decisions

How These Biomarkers Work Together

Your cancer is classified by combining these three results:

• Hormone receptor-positive (ER+ and/or PR+): Often treated with hormone therapy
• HER2-positive: Often treated with HER2-targeted therapies
• Triple-negative (ER-, PR-, HER2-): Doesn't respond to hormone or HER2-targeted therapies, so chemotherapy becomes more central to treatment

Additional Biomarker Testing

According to NCCN Guidelines, depending on your specific situation, your care team may also test for:

Genetic Mutations (for specific patients)

• BRCA1 and BRCA2 mutations: These genes normally help prevent cancer. When mutated, they increase breast cancer risk and may affect treatment options. BRCA testing is recommended if you have:

  • Triple-negative breast cancer
  • A significant family history of breast or ovarian cancer
  • Breast cancer diagnosed before age 45

• Other genes like PALB2, p53, CHEK2, and ATM may be tested depending on your family history and cancer characteristics

Mutation Testing

According to NCCN Guidelines, mutation testing (looking for changes in cancer genes) is more commonly done in metastatic (advanced) breast cancer to guide treatment selection.

Why Biomarkers Matter

These biomarkers help your oncology team:

• Predict how aggressive your cancer might be
• Determine which systemic therapies (chemotherapy, hormone therapy, targeted therapy) will be most effective
• Avoid treatments that won't work for your specific cancer
• Personalize your treatment plan

Questions to Ask Your Care Team

1. What are my specific ER, PR, and HER2 results?
2. What do these results mean for my treatment options?
3. Do I need genetic testing, and if so, why?
4. How will these biomarkers affect my treatment plan?
5. Will my biomarkers be retested during or after treatment?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.